Company Active LTD

Company profile

Motilent Limited

401 Authorization Required

Motilent Limited is a UK company with status active founded in 2013.

CRN
08730130
Founded
2013
Age
12

Overview

Legal name
MOTILENT LIMITED
Region
Unknown
Registered address
BEYOND ALDGATE TOWER
2 LEMAN STREET
LONDON
UNITED KINGDOM
E1 8FA
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

Motilent Limited
No active corporate controller recorded.

Latest accounts

Financial period: 1 Apr 2024 to 31 Mar 2025

FULLACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
20

Company events

Reference milestones and recent Companies House filing stream events.

5 events
11 Mar
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Dec
2026

Accounts due

Accounts Due

Next accounts due date

25 Feb
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Mar
2025

Accounts filed

Accounts

Last accounts made up date

14 Oct
2013

Incorporated

Inception

Company registered at Companies House

Public funding

3 awards
First funded
2020
Funded years
2020, 2023, 2024
Age at first award
6 years

Projects

2024 EU-Funded Lead participant

Synthetic hEalthcare dAta goveRnanCe Hub

1 Oct 2024 to 30 Sep 2028

Awarded
£486,861
Total cost £486,861

The objectives of SEARCH are truly ground-breaking, seeking to enable extensive data aggregation and analysis while safeguarding the integrity and privacy of original datasets through synthetically derived proxies. This initiative is designed to address biomedical challenges in Europe and offer translational solutions that will ultimately contribute to th...

2023 EU-Funded Lead participant

Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseases

1 Apr 2023 to 31 Mar 2028

Awarded
£263,610
Total cost £263,610

Fibrostenosis is the driving reason for the persistent need in bowel resections in inflammatory bowel diseases (IBD). Current IBD therapies are limited to solely targeting inflammation. While these therapies in some, but not all, cases lead to symptomatic disease remission, recurrent flares interspaced with periods of remission will still result in cumula...

2020 Feasibility Studies Lead participant

Quantitative Reporting in Crohn’s Disease: Maximising available MRI data to better direct patient treatment, speed up treatment decisions and improve healthcare outcomes

1 Jun 2020 to 30 Nov 2020

Awarded
£182,000
Total cost £182,000

no public description

2020 Collaborative R&D Lead participant

Quantitative Reporting in Crohn’s Disease: Maximising available MRI data to better direct patient treatment, speed up treatment decisions and improve healthcare outcomes

1 Apr 2020 to 31 Mar 2023

Awarded
£989,649
Total cost £1,413,784

Awaiting Public Project Summary

Product types

Collaborative R&D EU-Funded Feasibility Studies